Back to Search Start Over

Investigating modifiable pathways in psoriasis: A Mendelian randomization study.

Authors :
Chalitsios CV
Georgiou A
Bouras E
Evangelou E
Gill D
Tsilidis KK
Tzoulaki I
Source :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Mar; Vol. 88 (3), pp. 593-601. Date of Electronic Publication: 2022 Nov 09.
Publication Year :
2023

Abstract

Background: Potentially modifiable risk factors have previously been investigated only in conventional observational studies.<br />Objective: To assess whether genetically predicted exposures to modifiable factors are associated with the risk of psoriasis.<br />Methods: Two-sample Mendelian randomization (MR) analysis.<br />Results: An increased risk of psoriasis was noted for genetically predicted lifetime smoking index (odds ratio [OR] <subscript>MR-IVW</subscript>  = 2.11; 95% confidence interval [CI], 1.28-3.51), childhood (OR <subscript>MR-IVW</subscript>  = 1.40; 95% CI, 1.14-1.71) and adult body mass index (OR <subscript>MR-IVW</subscript>  = 1.63; 95% CI, 1.32-2), waist (OR <subscript>IVW</subscript>  = 1.86; 95% CI, 1.31-2.64), and hip circumference (OR <subscript>MR-IVW</subscript>  = 1.55; 95% CI, 1.15-2.07). Protective association was also reported between genetically predicted longer sleep duration (OR <subscript>MR-IVW</subscript>  = 0.56; 95% CI 0.37-0.84) and increased years of education (OR <subscript>MR-IVW</subscript>  = 0.78; 95% CI, 0.62-0.98). This effect of education persisted in multivariable MR after adjusting for genetic predictors of smoking and adult body mass index (OR <subscript>MVMR-IVW</subscript>  = 0.72; 95% CI, 0.56-0.92).<br />Limitations: It was not possible to stratify for psoriasis severity.<br />Conclusion: Smoking cessation and prevention of obesity are important strategies for decreasing the incidence of psoriasis. Similarly, targeting education inequality is expected to lead further to reductions in cases of psoriasis.<br />Competing Interests: Conflicts of interest D.G is employed part-time by Novo Nordisk, outside of the submitted work. The other authors have none to disclose.<br /> (Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-6787
Volume :
88
Issue :
3
Database :
MEDLINE
Journal :
Journal of the American Academy of Dermatology
Publication Type :
Academic Journal
Accession number :
36370904
Full Text :
https://doi.org/10.1016/j.jaad.2022.11.010